Biorce raises $52M to support global rollout of its AI clinical trial platform

Barcelona-based health AI company Biorce has secured a significant $52 million Series A funding round, signalling a major push to enhance global clinical trial processes. This substantial investment, led by DST Global Partners with participation from existing investors Norrsken VC and YZR Capital, underscores the growing confidence in AI's capacity to revolutionize drug development and brings Biorce's total funding to over $60 million. At the heart of Biorce's innovation is its AI-native Aika platform, designed to fundamentally improve clinical trial design and execution. The platform aims to dramatically shorten preparation timelines and minimize protocol amendments, which in traditional models can cause costly delays of up to six weeks per amendment and incur substantial financial burdens, impacting the speed at which new therapies reach patients. The implications of Biorce's technology are far-reaching, impacting pharmaceutical companies, biotech firms, and contract research organizations. By leveraging a dataset of roughly one million clinical trials, Aika is poised to reduce errors, anticipate risks, and streamline interactions with regulatory bodies like the FDA and EMA, ultimately accelerating the delivery of life-saving treatments across various therapeutic areas.